Therapeutic Potential of HO-1 in Autoimmune Diseases

Inflammation

Volumn 37, Issue 5, 2014, Pages 1779-1788

  Li, Bao Zhu ^a   Guo, Biao ^a   Zhang, Hai Yan ^a   Liu, Juan ^a   Tao, Sha Sha ^a   Pan, Hai Feng ^a   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

anti inflammation; autoimmune diseases; carbon monoxide; heme oxygenase 1; immunomodulation

Indexed keywords

CYCLOOXYGENASE 2; HEME OXYGENASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; DISEASE PREDISPOSITION; ENZYME INHIBITION; GENE THERAPY; GENETIC POLYMORPHISM; HUMAN; IMMUNOREGULATION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NONHUMAN; OXIDATIVE STRESS; PROMOTER REGION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; AUTOIMMUNE DISEASES; DRUG EFFECTS; ENZYMOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; HEME OXYGENASE-1; HUMANS; INFLAMMATION; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84918808258     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9908-z     Document Type: Article

References (72)

1. Kapturczak, M.H., C. Wasserfall, T. Brusko, et al. 2004. Heme oxygenase-1 modulates early inflammatory responses: Evidence from the heme oxygenase-1-deficient mouse. The American Journal of Pathology 165: 1045–1053.
2. Tenhunen, R., H.S. Marver, and R. Schmid. 1968. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proceedings of the National Academy of Sciences of the United States of America 61: 748–755.
3. Durante, W. 2011. Protective role of heme oxygenase-1 against inflammation in atherosclerosis. Frontiers in Bioscience (Landmark Ed) 16: 2372–2388.
4. Kobayashi, H., M. Takeno, T. Saito, et al. 2006. Regulatory role of heme oxygenase 1 in inflammation of rheumatoid arthritis. Arthritis and Rheumatism 54: 1132–1142.
5. Minamino, T., H. Christou, C.M. Hsieh, et al. 2001. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proceedings of the National Academy of Sciences of the United States of America 98: 8798–8803.
6. Haines, D.D., I. Lekli, P. Teissier, I. Bak, and A. Tosaki. 2012. Role of haeme oxygenase-1 in resolution of oxidative stress-related pathologies: Focus on cardiovascular, lung, neurological and kidney disorders. Acta Physiologica (Oxford, England) 204: 487–501.
7. Blancou, P., V. Tardif, T. Simon, et al. 2011. Immunoregulatory properties of heme oxygenase-1. Methods in Molecular Biology 677: 247–268.
8. Fagone, P., F. Patti, K. Mangano, et al. 2013. Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis. Journal of Neuroimmunology 261: 82–86.
9. Simon, T., I. Anegon, and P. Blancou. 2011. Heme oxygenase and carbon monoxide as an immunotherapeutic approach in transplantation and cancer. Immunotherapy 3: 15–18.
10. Poss, K.D., and S. Tonegawa. 1997. Heme oxygenase 1 is required for mammalian iron reutilization. Proceedings of the National Academy of Sciences of the United States of America 94: 10919–10924.
11. Yachie, A., Y. Niida, T. Wada, et al. 1999. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. The Journal of Clinical Investigation 103: 129–135.
12. Pae, H.O., G.S. Oh, B.M. Choi, et al. 2004. Carbon monoxide produced by heme oxygenase-1 suppresses T cell proliferation via inhibition of IL-2 production. Journal of Immunology 172: 4744–4751.
13. Burt, T.D., L. Seu, J.E. Mold, A. Kappas, and J.M. McCune. 2010. Naive human T cells are activated and proliferate in response to the heme oxygenase-1 inhibitor tin mesoporphyrin. Journal of Immunology 185: 5279–5288.
14. Hu, C.M., H.H. Lin, M.T. Chiang, P.F. Chang, and L.Y. Chau. 2007. Systemic expression of heme oxygenase-1 ameliorates type 1 diabetes in NOD mice. Diabetes 56: 1240–1247.
15. Xia, Z.W., W.W. Zhong, L.Q. Xu, et al. 2006. Heme oxygenase-1-mediated CD4+CD25high regulatory T cells suppress allergic airway inflammation. Journal of Immunology 177: 5936–5945.
16. Gu, Q., Q. Wu, M. Jin, et al. 2012. Heme oxygenase-1 alleviates mouse hepatic failure through suppression of adaptive immune responses. The Journal of Pharmacology and Experimental Therapeutics 340: 2–10.
17. Chauveau, C., S. Remy, P.J. Royer, et al. 2005. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood 106: 1694–1702.
18. Remy, S., P. Blancou, L. Tesson, et al. 2009. Carbon monoxide inhibits TLR-induced dendritic cell immunogenicity. Journal of Immunology 182: 1877–1884.
19. George, J.F., A. Braun, T.M. Brusko, et al. 2008. Suppression by CD4+ CD25+ regulatory T cells is dependent on expression of heme oxygenase-1 in antigen-presenting cells. The American Journal of Pathology 173: 154–160.
20. Park, D.J., A. Agarwal, and J.F. George. 2010. Heme oxygenase-1 expression in murine dendritic cell subpopulations: Effect on CD8+ dendritic cell differentiation in vivo. The American Journal of Pathology 176: 2831–2839.
21. Tardif, V., S.A. Riquelme, S. Remy, et al. 2013. Carbon monoxide decreases endosome-lysosome fusion and inhibits soluble antigen presentation by dendritic cells to T cells. European Journal of Immunology 43(11): 2832–2844.
22. Chora, A.A., P. Fontoura, A. Cunha, et al. 2007. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. The Journal of Clinical Investigation 117: 438–447.
23. Xia, Z.W., W.W. Zhong, J.S. Meyrowitz, and Z.L. Zhang. 2008. The role of heme oxygenase-1 in T cell-mediated immunity: The all encompassing enzyme. Current Pharmaceutical Design 14: 454–464.
24. Weaver, C.T., L.E. Harrington, P.R. Mangan, M. Gavrieli, and K.M. Murphy. 2006. Th17: An effector CD4 T cell lineage with regulatory T cell ties. Immunity 24: 677–688.
25. Deenick, E.K., and S.G. Tangye. 2007. Autoimmunity: IL-21: A new player in Th17-cell differentiation. Immunology and Cell Biology 85: 503–505.
26. Bettelli, E., Y. Carrier, W. Gao, et al. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235–238.
27. Zhang, Y., L. Zhang, J. Wu, C. Di, and Z. Xia. 2013. Heme oxygenase-1 exerts a protective role in ovalbumin-induced neutrophilic airway inflammation by inhibiting response in the immune cells Th17. The Journal of Biological Chemistry 288(48): 34612–34626.
28. Otterbein, L.E., M.P. Soares, K. Yamashita, and F.H. Bach. 2003. Heme oxygenase-1: Unleashing the protective properties of heme. Trends in Immunology 24: 449–455.
29. Lee, T.S., and L.Y. Chau. 2002. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nature Medicine 8: 240–246.
30. Mackern-Oberti, J.P., C. Llanos, L.J. Carreno, et al. 2013. Carbon monoxide exposure improves immune function in lupus-prone mice. Immunology 140: 123–132.
31. Otterbein, L.E., F.H. Bach, J. Alam, et al. 2000. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nature Medicine 6: 422–428.
32. Bilban, M., F.H. Bach, S.L. Otterbein, et al. 2006. Carbon monoxide orchestrates a protective response through PPARgamma. Immunity 24: 601–610.
33. Woo, C.H., M.P. Massett, T. Shishido, et al. 2006. ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor delta (PPARdelta) stimulation. The Journal of Biological Chemistry 281: 32164–32174.
34. Nakahira, K., H.P. Kim, X.H. Geng, et al. 2006. Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. The Journal of Experimental Medicine 203: 2377–2389.
35. Wang, X.M., H.P. Kim, K. Nakahira, S.W. Ryter, and A.M. Choi. 2009. The heme oxygenase-1/carbon monoxide pathway suppresses TLR4 signaling by regulating the interaction of TLR4 with caveolin-1. Journal of Immunology 182: 3809–3818.
36. Chin, B.Y., G. Jiang, B. Wegiel, et al. 2007. Hypoxia-inducible factor 1alpha stabilization by carbon monoxide results in cytoprotective preconditioning. Proceedings of the National Academy of Sciences of the United States of America 104: 5109–5114.
37. Rahman, A., and D.A. Isenberg. 2008. Systemic lupus erythematosus. The New England Journal of Medicine 358: 929–939.
38. Herrada, A.A., C. Llanos, J.P. Mackern-Oberti, et al. 2012. Haem oxygenase 1 expression is altered in monocytes from patients with systemic lupus erythematosus. Immunology 136: 414–424.
39. Chung, S.W., X. Liu, A.A. Macias, R.M. Baron, and M.A. Perrella. 2008. Heme oxygenase-1-derived carbon monoxide enhances the host defense response to microbial sepsis in mice. The Journal of Clinical Investigation 118: 239–247.
40. Avihingsanon, Y., T. Benjachat, A. Tassanarong, P. Sodsai, V. Kittikovit, and N. Hirankarn. 2009. Decreased renal expression of vascular endothelial growth factor in lupus nephritis is associated with worse prognosis. Kidney International 75: 1340–1348.
41. Takeda, Y., M. Takeno, M. Iwasaki, et al. 2004. Chemical induction of HO-1 suppresses lupus nephritis by reducing local iNOS expression and synthesis of anti-dsDNA antibody. Clinical and Experimental Immunology 138: 237–244.
42. Burmester, G.R., B. Stuhlmuller, G. Keyszer, and R.W. Kinne. 1997. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Arthritis and Rheumatism 40: 5–18.
43. Feldmann, M., F.M. Brennan, and R.N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annual Review of Immunology 14: 397–440.
44. Choy, E.H., and G.S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. The New England Journal of Medicine 344: 907–916.
45. Devesa, I., M.L. Ferrandiz, M.C. Terencio, L.A. Joosten, W.B. van den Berg, and M.J. Alcaraz. 2005. Influence of heme oxygenase 1 modulation on the progression of murine collagen-induced arthritis. Arthritis and Rheumatism 52: 3230–3238.
46. Kirino, Y., M. Takeno, S. Murakami, et al. 2007. Tumor necrosis factor alpha acceleration of inflammatory responses by down-regulating heme oxygenase 1 in human peripheral monocytes. Arthritis and Rheumatism 56: 464–475.
47. Kitamura, A., K. Nishida, T. Komiyama, et al. 2011. Increased level of heme oxygenase-1 in rheumatoid arthritis synovial fluid. Modern Rheumatology 21: 150–157.
48. Devesa, I., M.L. Ferrandiz, I. Guillen, J.M. Cerda, and M.J. Alcaraz. 2005. Potential role of heme oxygenase-1 in the progression of rat adjuvant arthritis. Laboratory Investigation 85: 34–44.
49. Benallaoua, M., M. Francois, F. Batteux, et al. 2007. Pharmacologic induction of heme oxygenase 1 reduces acute inflammatory arthritis in mice. Arthritis and Rheumatism 56: 2585–2594.
50. Chi, P.L., Y.W. Chen, L.D. Hsiao, Y.L. Chen, and C.M. Yang. 2012. Heme oxygenase 1 attenuates interleukin-1beta-induced cytosolic phospholipase A2 expression via a decrease in NADPH oxidase/reactive oxygen species/activator protein 1 activation in rheumatoid arthritis synovial fibroblasts. Arthritis and Rheumatism 64: 2114–2125.
51. Bonelli, M., A. Savitskaya, C.W. Steiner, et al. 2012. Heme oxygenase-1 end-products carbon monoxide and biliverdin ameliorate murine collagen induced arthritis. Clinical and Experimental Rheumatology 30: 73–78.
52. Noseworthy, J.H., C. Lucchinetti, M. Rodriguez, and B.G. Weinshenker. 2000. Multiple sclerosis. The New England Journal of Medicine 343: 938–952.
53. Le, W.D., W.J. Xie, and S.H. Appel. 1999. Protective role of heme oxygenase-1 in oxidative stress-induced neuronal injury. Journal of Neuroscience Research 56: 652–658.
54. Schluesener, H.J., and K. Seid. 2000. Heme oxygenase-1 in lesions of rat experimental autoimmune encephalomyelitis and neuritis. Journal of Neuroimmunology 110: 114–120.
55. Liu, Y., B. Zhu, L. Luo, P. Li, D.W. Paty, and M.S. Cynader. 2001. Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. Neuroreport 12: 1841–1845.
56. Swanborg, R.H. 1995. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clinical Immunology and Immunopathology 77: 4–13.
57. Rivers, T.M., and F.F. Schwentker. 1935. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. The Journal of Experimental Medicine 61: 689–702.
58. Chen, S.J., Y.L. Wang, W.T. Lo, et al. 2010. Erythropoietin enhances endogenous haem oxygenase-1 and represses immune responses to ameliorate experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology 162: 210–223.
59. DeVry, C.G., M. Valdez, L. Gao, et al. 2004. RDP58, a novel immunomodulatory peptide, ameliorates clinical signs of disease in the Lewis rat model of acute experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 152: 33–43.
60. Tzima, S., P. Victoratos, K. Kranidioti, M. Alexiou, and G. Kollias. 2009. Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN-beta production. The Journal of Experimental Medicine 206: 1167–1179.
61. Chakrabarty, A., M.R. Emerson, and S.M. LeVine. 2003. Heme oxygenase-1 in SJL mice with experimental allergic encephalomyelitis. Multiple Sclerosis 9: 372–381.
62. Tisch, R., and H. McDevitt. 1996. Insulin-dependent diabetes mellitus. Cell 85: 291–297.
63. Di Filippo, C., R. Marfella, S. Cuzzocrea, et al. 2005. Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes 54: 803–810.
64. Rodella, L., B.D. Lamon, R. Rezzani, et al. 2006. Carbon monoxide and biliverdin prevent endothelial cell sloughing in rats with type I diabetes. Free Radical Biology & Medicine 40: 2198–2205.
65. Li, M., S. Peterson, D. Husney, et al. 2007. Long-lasting expression of HO-1 delays progression of type I diabetes in NOD mice. Cell Cycle 6: 567–571.
66. Huang, S.H., C.H. Chu, J.C. Yu, et al. 2010. Transgenic expression of haem oxygenase-1 in pancreatic beta cells protects non-obese mice used as a model of diabetes from autoimmune destruction and prolongs graft survival following islet transplantation. Diabetologia 53: 2389–2400.
67. Abdel Aziz, M.T., M.F. El-Asmar, E.G. El Nadi, et al. 2010. The effect of curcumin on insulin release in rat-isolated pancreatic islets. Angiology 61: 557–566.
68. Abdel Aziz, M.T., M.F. El-Asmar, I.N. El-Ibrashy, et al. 2012. Effect of novel water soluble curcumin derivative on experimental type- 1 diabetes mellitus (short term study). Diabetology and Metabolic Syndrome 4: 30.
69. Shibahara, S. 2003. The heme oxygenase dilemma in cellular homeostasis: New insights for the feedback regulation of heme catabolism. The Tohoku Journal of Experimental Medicine 200: 167–186.
70. Wagener, F.A., E.J. Toonen, L. Wigman, et al. 2008. HMOX1 promoter polymorphism modulates the relationship between disease activity and joint damage in rheumatoid arthritis. Arthritis and Rheumatism 58: 3388–3393.
71. Cordova, E.J., A. Martinez-Hernandez, J. Ramirez-Bello, et al. 2012. HMOX1 promoter (GT)n polymorphim is associated with childhood-onset systemic lupus erythematosus but not with juvenile rheumatoid arthritis in a Mexican population. Clinical and Experimental Rheumatology 30: 297–301.
72. Rueda, B., J. Oliver, G. Robledo, et al. 2007. HO-1 promoter polymorphism associated with rheumatoid arthritis. Arthritis and Rheumatism 56: 3953–3958.